Publications

Patient-reported harm from NHS treatment or care, or the lack of access to care: a cross-sectional survey of general population prevalence, impact and responses.

Crocker H. et al, (2025), BMJ Qual Saf, 35, 30 - 42

Systematic review of health economic models for assessment and diagnosis of dementia

Kwon J. et al, (2025), Alzheimer's & Dementia: Behavior & Socioeconomics of Aging, 1

Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study.

Cardoso P. et al, (2025), Diabetes Obes Metab, 27, 4320 - 4329

Development of a brief assessment tool to identify children with probable anxiety disorders.

Reardon T. et al, (2025), JCPP Adv, 5

Protocol for the process evaluation for a cluster randomised controlled trial evaluating primary school-based screening and intervention delivery for childhood anxiety problems.

Williamson V. et al, (2025), BMJ Open, 15

Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry.

Lund LH. et al, (2024), Eur J Heart Fail, 26, 2487 - 2501

Influence of diabetes and obesity on ten-year outcomes after coronary artery bypass grafting in the arterial revascularisation trial.

Stefil M. et al, (2024), Clin Res Cardiol, 113, 1515 - 1522

Quality of care for secondary cardiovascular disease prevention in 2009-2017: population-wide cohort study of antiplatelet therapy use in Scotland.

Thalmann I. et al, (2024), BMJ Qual Saf, 33, 716 - 725

Extending mechanical thrombectomy service provision to 24/7: a break-even analysis.

Balami JS. et al, (2024), BMC Health Serv Res, 24

The societal economic impact of vision impairment in adults 40 years and above: findings from the National Eye Survey of Trinidad and Tobago.

Braithwaite T. et al, (2024), Eye (Lond), 38, 2124 - 2133

Minimal clinically important differences in patient-reported outcomes after coronary artery bypass surgery in the arterial revascularization trial.

Masterson Creber R. et al, (2024), Eur J Cardiothorac Surg, 66

Health-related quality of life and healthcare costs of symptoms and cardiovascular disease events in patients with atrial fibrillation: a longitudinal analysis of 27 countries from the EURObservational Research Programme on Atrial Fibrillation general long-term registry.

Walli-Attaei M. et al, (2024), Europace, 26

Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study.

Mihaylova B. et al, (2024), Lancet Reg Health Eur, 40

Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.

Wu R. et al, (2024), Br J Gen Pract, 74, e189 - e198

Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.

Morrow LM. et al, (2024), J Diabetes, 16

Search results (492)